

COMMONWEALTH OF AUSTRALIA

Instrument number PB 28 of 2008

Amendment special arrangements under subsection 100(1) of the National Health Act 1953

I, DIANA MACDONELL, Acting Assistant Secretary, Pharmaceutical Evaluation Branch, Department of Health and Ageing, delegate of the Minister for Health and Ageing, make this instrument under subsection 100(1) of the *National Health Act 1953*.

Dated 1st February 2008

DIANA MACDONELL

Acting Assistant Secretary Pharmaceutical Evaluation Branch Department of Health and Ageing

<u>Amendment Special Arrangements — Chemotherapy Pharmaceuticals Access</u> <u>Program</u>

1 Commencement

This instrument commences on 1 March 2008.

2 Amendment of PB 93 of 2007

Schedule 1 amends PB 93 of 2007.

Schedule 1 Amendments

[1] Schedule 1, item dealing with Pemetrexed

insert in the column headed "Circumstances" immediately before the existing circumstances:

In respect of the powder for I.V. infusion 100 mg (as disodium heptahydrate): In compliance with authority procedures set out in paragraph 14:
Locally advanced or metastatic non-small cell lung cancer, after prior platinum-based chemotherapy
Mesothelioma in combination with cisplatin
In respect of the powder for I.V. infusion 500 mg (as disodium heptahydrate):

[2] Schedule 2, item dealing with Oxaliplatin, Powder for I.V. infusion 50 mg

insert in the column headed "Brand" in alphabetical order:

Oxaliplan 50

[3] Schedule 2, item dealing with Oxaliplatin, Powder for I.V. infusion 100 mg

insert in the column headed "Brand" in alphabetical order:

Oxaliplan 100

[4] Schedule 2, item dealing with Pemetrexed

insert as first listing in the columns in the order indicated: